BioInvent Receives FDA Orphan Drug Designation for BI-1808 for the Treatment of T-cell Lymphoma
LUND, SE / ACCESS Newswire / March 20, 2025 /BioInvent International AB ("BioInvent") (Nasdaq Stockholm:BINV), a biotech ...
MPR1d
FDA Grants Traditional Approval to Keytruda for HER2+ Gastric/GEJ Cancer
When combined with trastuzumab and chemotherapy, treatment with pembrolizumab was associated with a statistically significant improvement in PFS and OS compared with placebo.
Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors
Antitumor activity observed with confirmed partial responses in 50% of patientsat highest dose tested to date, across ...
Business Wire14d
PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies Market Research 2025: Ivonescimab has Set the Bar for Competitors - Business, Pipeline and Competitor Analysis ...
The first-in-class and so far best-in-class PD-1xVEGF bispecific antibody ivonescimab has set ... clinical profile compared with anti-PD-1 pembrolizumab (Keytruda) and for economic terms of ...
Business Insider16d
Purple Biotech Granted New U.S. Patent for NT219 in Combination with EGFR Antibody Therapy, Enhancing Global IP Protection in Major Markets
to treat R/M SCCHN patients in combination with cetuximab or pembrolizumab. The Company is advancing CAPTN-3, a preclinical platform of conditionally activated tri-specific antibodies, which ...
Rheumatology Advisor3d
February 2025 Recap: Drug Pipeline Updates
The table is a review of notable updates that occurred in February 2025 for investigational products in development.
Akeso Announces The Publication of Its Phase III Clinical Trial Results for Ivonescimab in Head-to-Head Comparison with Pembrolizumab in The Lancet
Akeso, Inc. (9926.HK) ("Akeso" or the "Company") is excited to announce that the groundbreaking results of the Phase III clinical study (HARMONi-2/AK112-303) of its first-in-class PD-1/VEGF bispecific ...
Targeted Oncology6d
Kato Breaks Down FDA Approval of Tislelizumab in Esophageal Cancer
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma.
Healio3d
Two-drug regimen active in advanced endometrial cancer
A novel two-drug combination exhibited antitumor activity among certain women with advanced endometrial cancer, data ...